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The sole envelope glycoprotein spike on the surface of Human Immunodeficiency
Virus (HIV-1) is composed of two subunits: gp120 and gp41. The gp120 consists of
three domains: the inner domain, outer domain and bridging sheet, to which the viral
primary receptor CD4 binds and induces a conformational change in gp120 to expose
the co-receptor binding site. Previous studies have found that the outer domain of
gp120 is relatively more stable than the inner domain and bridging sheet. When
superimposed, the co-crystal structures of CD4-gp120 complex and VRC01-gp120
complex revealed that the CD4-binding site (CD4-BS) antibody VRC01 actually
mainly bound to the outer domain of the gp120. The outer domain (designed OD1) of
gp120 has been considered as an immunogen candidate but to be ineffective,
suggesting that structural-based modifications to the outer domain are required for
designing an effective vaccine immunogen. Previous studies in our laboratory have
introduced two disulfide bonds to stabilize the outer domain structure and named it
OD2, which significantly improved the immunogenicity when compared to the wildtype outer domain (OD1). In this project, based on the OD2 set of experiment, an
additional important mutation from serine to tryptophan at position 375 (S375W) in

the CD4-binding cavity was introduced to further stabilize the outer domain, which
was named OD3. The OD3 immunogen was expressed and purified in E. coli.
Subsequently, the purified OD3 immunogen was characterized in vitro and its
immunogenicity was tested in guinea pigs. In comparison to OD1 and OD2, the
results demonstrate the antibody titers and neutralizing activity were clearly higher in
OD3. It is suggested that the S/375W mutation stabilized the outer domain and further
improved the outer domain (OD) immunogenicity. In conclusion, this research has
used a structure-based approach to design HIV-1-1 vaccine immunogens based on the
gp120 outer domain (OD).
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Chapter 1: Literature review
Acquired immune deficiency syndrome, known as AIDS, is an immunodeficiency
disease caused by human immunodeficiency virus type 1, known as HIV-1-1. Since the
virus was discovered in 1981(1-4), more than 65 million people have been infected with
this virus, and more than 39 million people have died of AIDS-related diseases (5). An
astonishing fact is that the number of deaths caused by AIDS exceeds the total number
of death resulted from all the wars in the 20th century. Although scientists try to
elongate HIV-1 patients’ life to a higher extent, we currently still have no cure, and
have no effective vaccine to prevent the virus infection. While researchers all over the
world have united together to tackle this problem, there are still a lot of obstacles on
the way to the success. The year 2014 was sad for us: MH17, an aircraft taking more
than 100 HIV-1 field experts crashed by a missile attack, and no one survived this
disaster (6). While people in the whole world were criticizing the missile attack,
scientists in HIV-1 related field were grieving over the deaths of their colleagues. Yet
we are, and will still be working on this issue: public awareness has been raised
dramatically in developing countries; vaccine development is becoming promising;
antiviral therapeutic treatments are also becoming more effective. In the foreseeable
future, human beings will finally overcome this disease.
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Acquired Immune Deficiency Syndrome (AIDS)
AIDS is caused by HIV-1-1 infection. HIV-1-1 specifically attacks human immune
cells such as CD4+ T cells, dendritic cells and macrophages (7). The infected
lymphocytes are recognized as toxic pathogens by human cytotoxic CD8+ lymphocytes,
and are killed by them. When CD4+ T cells and other vital human lymphocytes decline
to a certain critical level, cell-mediated immunity is gradually destroyed, and people
infected with HIV-1 eventually die from the breakdown of their immune system.
Without any treatment, this whole process may take 9-12 years (8).

Human Immunodeficiency Virus （HIV-1）
Facts and Statistics
AIDS-related diseases have led to a total number of 39 million death since 1981, the
first reported case. In 2015, there were 37 million people living with HIV-1-1, and SubSaharan Africa accounts for 70% of HIV-1-1-infected population. Although we have
witnessed an increase of incidence in two years, the death rate and HIV-1-1-infected
growth rate has dropped down significantly. New HIV-1-1 infections have fallen by 35%
since 2000, and new HIV-1-1 infections among children have declined by 58% since
2000. By the end of 2015, AIDS-related deaths have fallen by 42% since the peak in
2004. By the year 2015, 5.8 million people were accessing antiretroviral therapy and
16 million of people had received antiretroviral therapy (ART) (5). With ART, people
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living with HIV-1-1 are able to have their lives extended to 30 or more years, making
their future promising (9).

HIV-1 Evolution and Genetic diversity
HIV-1 belongs to the genus lentivirus, which is a part of the family Retroviridae
(10)(11). HIV-1 is an enveloped, positive, single-stranded RNA virus. It was first
reported as syndrome caused by a new virus in 1981. It was then named HIV-1 in 1982,
and was finally isolated and characterized in 1983 (4). There are two types of HIV-1,
classified as

HIV-1-1

and

HIV-1-2.

HIV-1-2 originates from

a simian

immunodeficiency virus (SIV) that infects the Sooty Mangabey. Compared to HIV-11, HIV-1-2 is less infectious, less virulent, and thus is confined primarily to West Africa
(12). HIV-1-1 originates from an SIV which infects common chimpanzees and gorillas.
HIV-1-1 is divided into 4 groups, one major group named M group, and three minor
groups named group N, O and P.

Each group is believed to represent an independent

transmission of SIV into humans (13). The M group accounts for 90% of HIV-1-1
infections all over the world and is further divided into 11 clades, or subtypes. They are
named alphabetically from A to K. Among the subtypes, subtype A is most commonly
seen in West Africa; subtype B is widely spread in Europe, United States, Australia,
Thailand and Japan; and subtype C is the dominant from southern and eastern Africa,
India, and parts of China. Other subtypes are less transmissible and confined to smaller
areas (14).
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HIV-1 Transmission
The three major transmission pathways of HIV-1 are sexual contact, direct exposure to
infected blood or body fluids, and mother to child transmission during pregnancy or
breastfeeding (15). It is confirmed that other routes of transmission such as exposures
to feces, sweat, tears, or saliva (16). Among these three transmission pathways, sexual
contact (both heterosexual and homosexual contact) is responsible for the most frequent
transmission. Generally, HIV-1 transmission via heterosexual contact dominates
among all the transmission pathways worldwide, however, the incidence of homosexual
transmission is arising in developed countries (17). In Africa, the majority of
transmissions are through mother to child, and male to female sexual contact. However,
homosexual contact results in higher percentage of HIV-1-1 infection in some European
countries and the United States, which accounts for 64% of new cases of infection(18).
Oral sexual contact also transmit HIV-1-1 through blood from minor wounds, although
the risk of this is relatively low (19). The risk of transmission may increase when there
are other sexually transmitted infections (20) or ulcers (18). When genital ulcers are
exposed to infected blood or body fluids, the result is a five-fold increase of HIV-1-1
infection (18). The most effective protection in sexual pathway is the use of condoms
during any sexual intercourse, which can reduce the risk of transmission by 73%. (21).

Blood and body fluid transmissions account for the second most frequent mode of HIV1-1 transmission. This is particularly true in less-developed counties. By sharing
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needles and needle stick injuries, blood and blood product transfusions, or medical
injections with contaminated and unsterilized instruments, HIV-1-1 finds its way to
lead to a positive infection. In developed countries, examination of blood products
before a blood transfusion is conducted is usually very seriously considered, and thus
the risk of HIV-1-1 infection is negligible (about 1 in 1.5 million in the United States
in 2008) (22). While in less developed countries, HIV-1-1 screening and blood donor
selection are not conducted perfectly, so up to 15% of HIV-1-1 infections in those
countries actually comes from contaminated blood and blood product transfusions
(23)(24)

Mother-to-child is the third most frequent mode of HIV-1-1 transmission. This
transmission pathway causes 90% of cases in children infected with HIV-1-1 (25).
However, with appropriate treatment during pregnancy, the risk of mother-to-child
infection can be reduced to about 1% (25). A piece of good news is that during the year
2014, there were 220,000 cases of children who became newly infected with HIV-1-1,
decreasing from 520,000 in 2000 (5).

HIV-1-1 structure and genome
As shown in Figure 1, HIV-1-1 is positive, single-stranded RNA retrovirus. Two copies
of RNA strands are packaged in the viral capsid and enveloped by matrix protein and
lipid membrane. HIV-1-1 is roughly spherical (26). Its diameter is about 120 nm, which
is 60 times smaller than a human red blood cell (27). Viral RNAs carry all the genetic
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information and are the nucleotides materials responsible for encoding nine structural
and non-structural proteins. As shown in Figure 2, the whole genome contains 9749
base pairs, and nine open reading frames which are protected by two long terminal
regions on both the 3’ and 5’ sites. Among the nine open reading frames, there are three
large precursor proteins, named Gag, Pol and Env (28). These proteins are then post
transcriptionally cleaved into smaller structural and non-structural proteins. The viral
RNAs are tightly bound and protected by the nucleocapsid protein p7, and the late
assembly protein p6. Viral RNA-P7-P6 complex is carried by the capsid made up of
2000 copies of p24 (29) (30), and further covered by the matrix protein composed of
p17. All of these proteins are post transcriptionally cleaved from the Gag precursor
protein. The three most important non-structural proteins: integrase, reverse
transcriptase, and viral protease, are encoded in the Pol open reading frame. Regulatory
proteins such as Rev and Tat, and other auxiliary accessory proteins, such as Vpr, Vif,
Vpu, and Nef are encoded in smaller open reading frames (31) . Outside the matrix is
the lipid membrane layer. It is formed from human lymphocytes by taking the
advantage of their lipid bilayer. HIV-1-1 envelope glycoproteins gp120 and gp41 are
cleaved from their gp160 precursor encoded from Env open reading frame. These two
envelope protein subunits play a vital role in viral entry, and thus are the key to inhibitor
design and vaccine development (32, 33).

7

HIV-1-1 Viral Life Cycle
HIV-1-1 lives in human lymphocytes. HIV-1-1 becomes very fragile when it is exposed
in the environment outside of the body (34, 35), which reduces the amount of infectious
virus by 90%-99% in just several hours. However, when HIV-1-1 is exposed to a human
lymphocyte, this virus finds its way into it and makes the human lymphocyte a
reproductive reservoir. The CD4 molecule binds to gp120, followed by a significant
conformational change, which leads to the exposure of chemokine receptor on gp120.
On the surface of the cell, the chemokine receptor, either CCR5 or CXCR4, then binds
to gp120, which allows gp41 to penetrate the cell membrane, and thus fuels virus-cell
membrane fusion (34, 35).

Successful viral fusion results in delivery of viral RNA and non-structural proteins into
the cell. These important enzymes, including reverse transcriptase (RT), integrase,
protease, etc., serve in reverse-transcription, cDNA replication, and host genome
integration. Reverse transcriptase transcribes the single strand viral RNA into a
complementary DNA carrying viral genetic information. The cDNA and its
complement form a double-stranded viral DNA and the viral protease and integrase
insert viral DNA into human host chromosome (34, 35) . During replication and
transcription, the extremely error-prone reverse transcriptase generates cDNA with a
large number of mutations, which can result in immune evasion and drug resistance.
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Other unique features about the reverse transcriptase are its ribonuclease activity and
DNA-dependent DNA polymerase activity (36, 37).

NF-B is one of the cellular transcription factors that controls virus production after the
viral genome has been successfully integrated into the host chromosome (38). When
cytotoxic CD8+ T-cells become activated, NF-B is upregulated and allows the host
genome to actively produce viral particles. Viral non-structural and structural proteins
are produced along with host chromosome translation. During viral replication, the
integrated viral DNA is transcribed back into viral RNA, which then undergoes RNA
splicing and becomes viral mature mRNAs (39). Along with the translation, some viral
regulatory enzymes, including Tat, allows better viral production. Another enzyme,
Rev, can localize itself to the nucleus and bind to viral mRNA, making the viral mRNA
possible to transport out of the nucleus. With Tat and Rev, viral mRNAs leave the
nucleus (38), and these mRNAs either function as transcription and translation
materials, to produce viral non-structural or structural proteins, or function as new viral
genome copies. Viral mRNAs, structural proteins and non-structural proteins, are then
packaged and assembled in the Golgi apparatus, and leave the host cell when mature.
During maturation, the Env polyprotein gp160 is cleaved by furin protein in the Golgi
apparatus. The cleaved gp160 becomes two subunits, gp120 and gp41, which are noncovalently linked and form a heterodimer. Three gp120/gp41 heterodimers form a
homotrimer anchored by gp41 subunits on the surface of HIV-1-1 envelope. Virions
are finally become mature and are then able to infect neighboring cells (40, 41).
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Immune Response
Signs and Symptoms
When having unprotected sex with an HIV-1-1 infected individual, or having direct
exposure to HIV-1-1 infected blood or body fluid samples, people are at risk of getting
infected with HIV-1-1. Initial symptoms may be inconspicuous since large numbers of
individuals only develop influenza-like symptoms (42)(43), and some others have no
noticeable symptoms (44)(45). Most commonly reported initial HIV-1-1 symptoms are
fever, lymphadenopathy, rash, headache, and throat/mouth/genital inflammation (46).
Some opportunistic infections like gastrointestinal symptoms, and neurological
symptoms may occur (47). However, all symptoms are not severe, and usually
disappear without any treatment in one to two weeks (48). Considering the fact that
these symptoms are usually not specific, and are easy to “be cured”, HIV-1-1 infections
are often not being recognized or diagnosed. Typically, people who had unprotected
sex with an individual with HIV-1-1 before developing with such symptoms, are
suggested to have a HIV-1-1 antibody test 1-3 months after suspecting that they have
been exposed to HIV-1-1.

In most cases, an HIV-1-1-infected individual first develops the non-specific Flu-like
symptoms described above, then the immune system starts to eliminate the virus but
leaves some latent virus harboring in CD4+ T cells, Macrophages or Dendritic cells
(49). A patient will live normal life until HIV-1-1 progresses and AIDS or AIDS-related
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symptoms arise after several years. Without any treatment, this clinical latency may last
three to 20 years, with an average of eight years (50)(51)(52). During the latency,
patients may first experience asymptomatically, or just have a low-grade fever for a
short period of time, but at a later latency stage, CD4+ T cells are lost at a higher rate
and individuals will eventually progress to AIDS (53). Interestingly, there are some
exceptions: about 5% of HIV-1-1 infected individuals actually retain a high level of
CD4+ T cells for more than five years without any treatment (54)(55), these people are
known as “long-term non-progressors” (55); another group is known as “elite
suppressors” whose viral load is undetectable even without any treatment.

AIDS refers to HIV-1-1 post latency symptoms and AIDS associated diseases, which
is clinically defined by the number of CD4+ T cells declined to a certain critical level
(usually, below 200 CD4+ T cells per microliter) (56). Without any antiretroviral
treatment, individuals infected with HIV-1-1 develop these symptoms within 10 years,
and swiftly progress to death due to the depletion of the vast majority of CD4+ T-cells
and infectious virus domination in plasma. Opportunistic infectious disease develops
along with this stage and can be caused by almost any pathogens including bacteria,
viruses, fungi and parasites (57). HIV-1-1 patients at a later clinical state are also very
vulnerable to cancers. Kaposi’s sarcoma occurs in 10 to 20% of cases of HIV-1-1
infected patients, which becomes the most common cancer accompanying AIDS (58).
Lymphoma, leading to death in 16% of people living with HIV-1-1, is the second most
common cancer (59). Human papillomavirus (HPV) and Hepatitis C virus (HCV) are
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reported to co-infect with HIV-1-1 and these two viruses also lead to virus-induced
cancers.

Innate Immunity
Innate immunity refers to the non-specific in-born immunity. Innate immunity plays a
very important role in early HIV-1-1 defense. The innate immunity is also the subimmune system that bridges humoral and cell mediated adaptive immune response at a
later stage. Moreover, white blood cells serve in innate immunity and in the case of
HIV-1-1 infection, play a unique role in HIV-1-1 latency, which is a major barrier of
HIV-1-1 eradication.

During the first stage of HIV-1-1 infection (also referred to as acute HIV-1-1 infection),
HIV-1-1 viral particles can be recognized by phagocytes such as macrophages and
dendritic cells (60, 61). HIV-1-1 envelope proteins, viral mRNAs, and other viral
structural or non-structural proteins, are termed as viral pathogen-associated molecular
patterns (PAMPs) (61). These viral PAMPs are recognized by pathogen-recognition
receptors (PRRs) of infected cells which trigger a series of signaling cascades. These
signaling cascades result in an intracellular antiviral immune response such as a
production or upregulation of antiviral molecules including interferons, interleukins,
cytokines and chemokines (60) . These molecules and the phagocytes are also involved
in initiation of the adaptive immune system(62) . At the first infection stage, HIV-1-1
is recognized by a mode of PRR termed as Toll-like receptors (TLRs) (63). Among
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these TLRs, plasmacytoid dendritic cells (pDCs) unitize TLR7 and TLR9 to recognize
single-stranded RNA (ssRNA) and double-stranded DNAs (dsDNAs) (63), triggering
signaling cascades to control viral replication and reproduction.

Viral replication usually indicates a successful viral infection, however, in the case of
pDCs, TLR7 and TLR9 recognition usually does not require HIV-1-1 reproductive
infection (63). There therefore must be other PRRs recognition pathways being
activated in those infected cells. It has been demonstrated that the infected cells use
RIG-I-like receptors (RLR) and other PRRs such as DAI, IFI16, and AIM2 to recognize
viral DNAs. Biological interplay between viral DNAs and PRRs leads to transcriptional
activation of pro-inflammatory cytokines, chemokines, and type I interferons (I-IFNs)
(64, 65). For example, upon TLR7 recognition, I-IFNs are induced, and these IFNs bind
to IFN receptors on the surface of the infected and surrounding cells, which further
triggers other signaling cascades that activates the transcription and translation of many
IFN-stimulated genes (ISGs). ISGs are important in blocking viral replications. One of
the most important ISGs is IFI16 (66-68). As mentioned above, IFI16 serves a role as
PRR. IFI16 is both a nuclear and a cytosolic protein. This protein binds to cDNA under
the assistance of a hin domain (67). After HIV-1-1 has successfully entered and
replicated in the reservoir, the viral mRNAs are reversely transcribed into cDNA. IFI16
recognizes and captures viral DNA through hin domain, destroying HIV-1-1
replications (69). A knockdown of IFI16 study shows that the target host cells that
undergo HIV-1-1infection in the absence of IFI16, have a significant higher level of
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HIV-1-1 permissiveness and viral replication(68). Thus IFI16 are confirmed to be both
an HIV-1-1 PRR and a restriction factor.

RLRs are a family of DExD/H box RNA helicases that function as cytoplasmic sensors
of PAMPs. Among these RLRs, RIG-I functions in HIV-1-1-infected cells by binding
to HIV-1-1 mRNAs (70), which leads to activation of pro-inflammatory innate
immunity response to target cells. Importantly, RIG-I also contributes to crosstalk with
TRLs and other PRRs to modulate the adaptive immune response (71). Another sensor
that recognizes HIV-1-1 PAMPs in HIV-1-1-infected cells is the cyclic GMP-AMP
synthase (cGAS) (69), which recognizes and binds to HIV-1-1 reverse transcriptase in
its early replication cycle. cGAS contains an amino-terminal DNA binding domains
and a nucleotidyltransferase domain, which allows viral DNA binding and produces
cyclic GMP-AMP (cGAMP) (68, 72). cGAMP is a cellular factor that works along with
cGAS to induce ISGs. cGAMP also functions as a second signaling factor and binds to
an adaptor protein called STING. The cGAMP-STING complex activates a signaling
cofactor TBK1, and interferon regulatory factors INF3 and INF7 (72), which finally
stimulates antiviral effector genes. Transcriptional factors such as IRF3, IRF7 and NFkB, also drive the production of viral restriction factors (APOBEC, TRIM5a, SAMHD1,
and tetherin) (61, 73) limiting viral replication. Each of these factors has been heavily
studied. Recent studies found other restriction factors including SLFN11, IFITM and
MX2 (74-77). Interestingly, these factors are not highly expressed in resting cells only
until they are induced by IFN. SLFN11 is an RNA helicase-like protein that suppresses
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HIV-1-1 replication at a later stage, so it is also associated with control of HIV-1-1
chronic infections. IFITM is transmembrane protein that inhibits HIV-1-1 entry (77).
MX2 is GTPase that suppresses HIV-1-1 replication by stopping HIV-1-1 reverse
transcribed DNA integration into the host chromosome.

During the first few hours of HIV-1-1 infection, viruses successfully obtain
opportunities to tear into the mucosal epithelium and undergo further interactions with
conventional DCs (cDCs) and Monocytes (60). The HIV-1-1-bearing stromal cDCs
also have CD4 molecule and CCR5 coreceptor on the cell membrane for HIV-1-1
infection. Activation of cDCs leads virus degradation by the secretion of restriction
factors such as APOBEC3G and SAMHD1, to restrict HIV-1-1 replication (78). Also,
IFNs and Interleukins such as IL-12, IL-15 and IL-18 induced by the activated cDCs
are able to either inhibit viral replication or recruit the NK cells to kill the infected cDCs
(79) . However, HIV-1-1 uptake by the C-type lectin DC-SIGN on the surface of the
DC cell membrane blocks DC maturation thus resulting in DC dysfunction (80). DCSIGN binds to HIV-1-1 envelope glycoproteins to internalize virus by endocytosis.
Binding of DC-SIGN with HIV-1-1 envelope glycoproteins also facilitates HIV-1-1
transmission to CD4+ helper T cells. During the activation of cDCs, the plasmacytoid
DCs are also activated. pDCs recognition of HIV-1-1 is achieved by TLR7 and TLR9
recognition. Unlike cDCs, the recognition usually does not require productive HIV-11 infection. Both cDCs and pDCs interacts with CD4+ helper T cells and transmit
virions via the virological synapse cell (81, 82). Based on the new understanding of the
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viral transmission pathway, new ideas of blocking HIV-1-1 infection of CD4+ helper
cells could be reconsidered, and this understanding also bring us more insights into
HIV-1-1 antiretroviral drug design as well as vaccine development.

Acquired Immunity
Currently, many studies have shown a strong link between the activation of innate
immunity pathways and the adaptive immunity response (83, 84). Both the severity and
the duration of primary HIV-1-1 infection are associated with the speed of CD4+ T
cells lost in chronic infection, and they also positively correlate with the number of
deaths in the AIDS phase. So, the events during very early HIV-1-1 infection directly
have consequences for the disease. How does the immune activation indicate HIV-1-1
infection? It has been well recognized that HIV-1-1 pathogenicity is characterized by
both severe immunodeficiency and significant immune activation (85, 86). There is
growing evidence showing that lymphocytes obtained from HIV-1-1-infected patients
are found mostly in an activated stage (87). During the acquired immunity activation,
phenotypic activation markers on the surface of peripheral T cells and B cells are
expressed at a decently higher level regulated by IFNs and other regulatory factors
induced in the innate immunity phase, shown by an increased level of inflammatory
cytokines in plasma. A sooty mangabey monkey model study (88) suggested a positive
correlation between immune activation and immune deficiency. In the absence of
dramatic immune activation, sooty mangabeys infected with SIV showed no manifests
of infection but detected high level of SIV replication in plasma (89).

16

Cell Mediated Immunity and Viral Immune Evasion
The acquired immunity against HIV-1-1 begins with the uptake of virus by CD4+ T
helper cells. During initial infections, usually a few hours post HIV-1-1 uptake by either
pDCs or cDCs (90-92), the internalized HIV-1-1 virions are transmitted from DCs to
CD4+ T cells via virological synapse. HIV-1-1 recognizes and binds to CD4+ T cells
through the interplay between viral envelope protein gp120 and cellular membrane
receptor and coreceptor CD4 and CCR5 or CXCR4, followed by CD8+ cytotoxic T
cells killing infected CD4+ T cells (93). During the first week, HIV-1-1 rests in HIV1-1-bearing T lymphocytes and amplifies within the cells in draining lymph nodes.
HIV-1-1-bearing DCs present HIV-1-1 antigens to both CD4+ T cells and CD8+ T cells
via either MHC class II AND MHC class I (94). This activation of T lymphocytes in
draining lymph nodes results in the clonal expansion of HIV-1-1-specific CD8+ T cells
and HIV-1-1-specific B cells. After activation, HIV-1-1-specific antibodies generated
from B cell follicle start to neutralize viral particles and CD8+ T cells begin to eliminate
HIV-1-1 productively infected CD4+ T cells.

Typically, during virus progression, the activated adaptive immunity eliminates both
viruses and virus-infected cells. However, the outcome of HIV-1-1 infection is that after
about 10 years of HIV-1-1 latency (95), infected individuals finally end their lives in
immunodeficiency resulted AIDS. So, what are the reasons make our immune system
abnormal? And how does the virus escape from immune detection and establish viral
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latency? Unlike other viruses which target on non-lymphocytes, our working immune
system clears HIV-1-1-infected CD4+ lymphocytes. This can be achieved by CD8+
cytotoxic T cells, and NK cells, cytotoxic killing from which eventually results in
inadequate CD4+ T cells in plasma. Following initial HIV-1-1 infections, CD8+
cytotoxic T cells do help control virus proliferation. The infected cells present viral
peptide antigens by HLAs (human leukocyte antigens) to CD8+ cytotoxic T cells,
resulting in apoptosis of infected cells either by perforin generating holes in the target
cells, by granzymes, or by Fas ligand-Fas (CD95) induced cell death (91). CD8+
cytotoxic T cells also regulate the delivery of antiviral soluble factors to infected cells,
such as cytokines and IFN-gamma, which promote nearby cells becoming less
vulnerable to viral infection (96)(97)(98). Despite these strategies utilized by CD8+ T
cells work to some extent eliminated infected cells, the viral defense story is just a
beginning, for HIV-1-1 is a master of escaping from cytotoxic lymphocytes. Under the
selective pressure from CD8+ cytotoxic T cells, HIV-1-1 swiftly acquires mutations
against cytotoxic T cell killing. Strong evidence has been found suggesting two viral
protein, Nef and Env are responsible for viral immune evasion (99, 100). The Nef
protein is necessary for high viral loads in AIDS progression, but the most important
and well characterized function of Nef, is its role in antigen presentation during immune
evasion. An example is that during an adoptive transfer of cytotoxic T lymphocytes to
a HIV-1-1-infected patient, the transferred cytotoxic T lymphocytes swiftly and
effectively selected for viral variants contains a deletion mutation in Nef protein (101,
102). Another method of immune evasion for HIV-1-1 is that a mutation at the second
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residue of the Env epitope reduces binding affinity of peptide to MHC during the
cytotoxic T lymphocyte immune response domination. This result indicates that Env
mutations can be another immune evasion strategy used by HIV-1-1 during cytotoxic
T lymphocytes antiviral selection. Other viral proteins that play roles in immune
evasion include Gag and Pol. These viral proteins allow the virus to replicate without
recognition by the host (103, 104).

To summarize, strategies of HIV-1-1 escaping cytotoxic T lymphocyte-mediated
immunity include: If infected CD4+ T cells are successfully eradicated by CTL killing,
the resulting substantial loss of CD4+ T cells will directly influence T helper cell
function, and this finally undermines CD8+ T cells immune response to clear infection.
On the other hand, HIV-1-1 evolves to obtain antigenic variability through the errorprone-reverse transcriptase resulting in mutations. These viral mutations can result in
the dysfunction of cytotoxic T lymphocytes in viral recognition, viral replication
inhibition, or viral proliferation. Eventually, the repeated T cell activation ends in T cell
exhaustion and leads to chronic HIV-1-1 infection.

Humoral Immunity and Viral Immune Evasion
During early HIV-1-1 infection, typically 1-4 weeks post infection, CD4+ T cells
activated by DCs presenting antigens via MHC II differentiate into T follicular helper
cells and migrate into the B cell follicle (105, 106)(107). HIV-1-1-specific B cell and
early antibody responses are established in the interplay of follicular DCs, follicular B
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cells and follicular helper T cells (108). In the early immune activation stage, proinflammatory cytokines mediated from innate immune response events lead to the
increase of turnover and polyclonal activation of B cells (109). This however will
results in either increased B cell apoptosis, follicular hyperplasia, or mature B cell
activation. A successful B cell maturation and memory B cell differentiation guided by
HIV-1-1 infection establishes the foundation for HIV-1-1-specific antibody production.
However, neutralizing antibodies against autologous HIV-1-1 strains develop slowly,
usually no earlier than 12 weeks post initial infection (110), and what is worse, even
though about 20% of HIV-1-1 patients develop neutralizing antibodies against HIV-11, a majority of these antibodies are of only moderate degree of neutralization and
aroused after years of infection (106, 111). It is thus important to look at B cells at their
early response to HIV-1-1 infection to understand why a neutralizing antibody response
cannot be acquired in acute infection as is the case in other viral infections.

The first detectable B cell response is found on day 8 post infection, whereas the first
detectable antibody response appears on day 13 post infection. These early induced
antibodies are however non-neutralizing antibodies against either gp41 or gp120 (111115). It is still unknown why these early phase antibodies are non-neutralizing. One
possible reason is that denatured or non-functional Env forms may be dominant in the
antigen pool (116, 117). The first neutralizing antibodies that induce escape mutants
develop 12 weeks post infection (118-120). Although studies have characterized a
number of neutralizing antibodies, these neutralizing antibodies majorly bind to the
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highly conserved regions of gp120 or gp41. For example, the monoclonal antibodies
b12 and VRC01, neutralize virus by specific binding to the CD4-binding site on gp120.
Another example would be the monoclonal antibodies that recognize the membraneproximal external region of gp41, such as 2F5, Z13 and 4E10 (120). Observations based
on the neutralizing antibodies binding locus reveal that the HIV-1-1 variable loops
under highly-shielded glycans create an antigenic barrier for antibodies neutralizing
either HIV-1-1 envelope core domains, or HIV-1-1 envelope variable loops.

Reasons for the broad-specificity, poor neutralizing, and rarely induced antibodies are
complex. First, as mentioned above, HIV-1-1 escapes antibody recognition by the errorprone reverse transcriptase-resulted antigenic mutations. Under antibody selection,
more than 95% of gp120 nucleotide changes resulted in an amino acid change (121).
Second, during HIV-1-1 progressive infection, follicular B cells are damaged by virusinduced and pro-cytokine induced apoptosis. The loss of follicular B cells has a direct
influence on antibody production, resulting either in a poor antibody response or
hypergammaglobulinemia. This damage further contributes to substantial loss of
germinal centers (about 50%) (122) and gradually progresses to HIV-1-1 chronic
infection. Third, during the chronic and advanced infection, CD4+ T cell lymphopenia
stimulates the secretion of IL-7, which increases the number of immature transitional
B cells. The consequence of expansion of immature B cells promotes a declined B cell
response to HIV-1-1 antigens. In addition, Nef mediated class-switch recombination,
during the expansion of immature B cells and naive mature B cells, results in the paucity
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of HIV-1-1-specific lgA at mucosal sites (122). At a later AIDS stage, inadequate CD4+
T helper cells are not functional enough to transit the decreased number of resting
memory B cells or splenic marginal zone B cells into memory B cells, which ends up
with memory B cell exhaustion. Taken together, the antigenic variability of HIV-1-1
envelope proteins, the vast damage in both germinal centers and follicular B cells, the
loss of CD4+ T helper cells and the exhausted memory B cells are eventually not able
to produce high affinity broadly neutralizing antibodies against HIV-1-1 progression.

HIV-1-1 Viral Latency
HIV-1-1 can infect both activated and non-activated, resting CD4+ T cells. Infection of
activated CD4+ T cells recruits CD8+ T cell cytotoxic killing and results in a substantial
depletion of CD4+ T cells. Whereas infection of resting CD4+ T cells usually leads to
viral latency. Viral latency is therefore a major challenge for virus eradication, even
under the treatment of highly active antiretroviral therapy (HAART) (123). In a normal
T cell immunity model, naive CD4+ T cells are activated by antigens presented by
antigen presenting cells (APCs). Following activation, CD4+ T cells start clonal
proliferation, during which, a majority of T cells undergo apoptosis and some effector
T cells differentiate into memory T cells. Other naive or memory T cells stay at the G0
phase of the cell cycle. However, during HIV-1-1 infection, viral genomes are reverse
transcribed and replicated into double-stranded cDNAs (dscDNAs )(124). The
dscDNAs are relatively unstable and exist in the cytosol. This is called a reversible preintegration latent state. However, when ATP is abundant in the cytosol, pre-integration
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state dscDNAs are permanently integrated into the host genome. The provirus after
successful integration remains quiescent before another cycle of immune activation.
These latent HIV-1-1 provirus bearing CD4+ T cells can be differentiated into memory
CD4+ T cells (125), and the nightmare for the host starts from here. As the antigens
fade, most effector T cells die by apoptosis, but a small portion of T cells remains as
memory T cells, and carry a permanent HIV-1-1 genome in their chromosome (126,
127). Some of these memory CD4+ T cells transit into a resting state that have an
extended lifespan and lack the markers for T cell activation. These virus-bearing resting
CD4+ T cells are thus not recognized by immune system and are less likely to be
activated during HIV-1-1 progression (128, 129). Viral latency is therefore established.

Anti-HIV-1-1 Therapy Development against AIDS
Antiretroviral Therapy
There is no cure for AIDS at the moment. Neither antiretroviral therapy (ART) nor a
protective vaccine can eliminate the virus or cure the disease. However, with ART or
HAART, HIV-1-1 infected individuals are able to live with HIV-1-1 for a longer time
and have their life extended to a close-to-normal life span. Also, ART does great job in
preventing mother-to-child HIV-1-1 transmission when treatment is given at a very
early stage to both child and mother. In the absence of any treatment, mother-to-child
transmission ranges from 15% to 45%, and ART brings the number down to below 5%
(130). This ART also provides optimal efficacy of reducing HIV-1-1 transmission
during sexual contact, reducing viremia and transmission by more than 96% (131)(132).
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Before given any ART, infected individuals are advised to undergo some tests to
examine the patient’s medical history, to determine the best choices of medicine, or to
avoid potential side effects. These tests includes, but not confined to, complete blood
count (including CD4+ T cell count), urinalysis, liver and kidney function tests,
infectious disease or sexually transmitted diseases tests, and a coreceptor tropism assay.
Typically, ART consists of several classes of HIV-1-1 medicines, and each individual
may take a regimen of different medicines in combination. The anti-HIV-1-1 medicine
classes are: non-nucleoside reverse transcriptase inhibitors (NNRTIs), which prevents
HIV-1-1 reverse transcriptase converting viral RNA to cDNA; nucleoside reverse
transcriptase inhibitors (NRTIs), which also prevents reverse transcription; protease
inhibitors, which inhibit viral-cleavage of the host genome; fusion inhibitors (e.g. T20),
which blocks virus-cell membrane fusion; CCR5 antagonists (e.g. Maraviroc), which
inhibits viral entry through coreceptor blocking; and integrase strand transfer inhibitors
(INSTIs) (133). There are however side effects that come with these medical treatments.
Physicians prescribing ART medicines always try to find a right combination of
medicines without eliciting too many side effects. However, these drugs may lead to
some short-term problems such as diarrhea, fatigue or headaches etc., or long-term side
effects such as lipodystrophy, insulin resistance, and lactic acidosis etc. The short-term
side effects usually last and fade from days to a month, but people suffering from the
long-term side effects should consider seeing their doctors periodically (134). Drug
resistance is another problem. HIV-1-1 mutates during their replications, and the
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mutations selected by antiretroviral drugs will gradually decrease antiretroviral drugs
efficacy.

Immunotherapy
Immunotherapy

is

another

way

of

treating

HIV-1-1-infected

individuals.

Immunotherapy refers to passively transferring HIV-1-1-specific neutralizing
antibodies to HIV-1-1 infected patients. However, pre-clinical and clinical trials of
these therapies all have failed to neutralize viruses (135-137). Therefore
immunotherapy against HIV-1-1 had been abandoned due to its ineffectiveness for
many years. However, recent studies taking advantage of novel strategies such as cellbased immunotherapy successfully suppressed HIV-1-1 in infected humans. On June,
2015, Caskey M et al. proved that HIV-1-1 viremia can be suppressed in HIV-1-1
infected humans by passive transfer of a monoclonal antibody named 3BNC117 (138).
Based on the single-cell-based antibody cloning methods, a new generation of potent
broadly neutralizing antibodies have been uncovered (139-142), making it possible for
researchers to produce large amount of broadly neutralizing antibodies (bNAbs). These
bNAbs have shown promising protection and viremia suppression in humanized mice
and nonhuman primates (143-145). In addition, a very recent study carried out by
Nancy Haigwood in 2016 (146), showed that by passively transferring human bNAbs
as a cocktail of PGT121 and VRC07-523 to infant macaques, SHIV-1 infection can be
halted with no viral emergence even after CD8+ T cell depletion. This results suggest
that this human bNAb cocktail immunotherapy can eliminate both viral foci and viral
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reservoirs at very early stage, making this immunotherapy promising to completely
eradicate HIV-1-1 and stop HIV-1-1 infection in human infants.

Vaccine Development against AIDS
The typhoid vaccine against typhoid bacterium was commercially available after a
105 year endeavor since pathogen had been discovered. A pertussis vaccine was
available 89 years after the first reported case. It took us 47 years to develop a vaccine
against polio and 42 years to develop a vaccine against measles. It therefore seems
quite understandable that over 35 years of HIV-1-1 vaccine research has not provided
us with an effective HIV-1-1 vaccine. We must however realize that the time course
for those released vaccines was reducing, and it only took us 16 years to develop a
vaccine against the hepatitis B virus. It is predictable that at this age an effective
vaccine for HIV-1-1 is coming in the foreseeable future.

Traditional vaccine strategies such as subunit, killed or live attenuated vaccines are
not protective against HIV-1 infection. These vaccines either induce non-bNAbs or
NAbs but strain specific, so that the low bNAb content is inadequate to have antibody
protection against HIV-1-1 infection. The first generation HIV-1-1 vaccine, typically
is represented by the AIDSVAX gp120 subunit vaccine, stimulates antibodies towards
HIV-1-1 envelope glycoproteins, but proved to be non-neutralizing, and thus failed to
protect vaccinated individuals from HIV-1 infection (147). The second generation,
named the STEP vaccine, uses adenovirus serotype 5 virus as backbone vector, to
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carry HIV-1-1 Gag, Pol and Nef genes, expressing these HIV-1 viral proteins. This
design was predicted to stimulate CD8+ T cell mediated immunity against HIV-1, but
again showed no effective protection (148, 149). After the above two failed trials, a
third generation vaccine was created (or we should call it a third efficacy trial,
because it utilizes a combination of two vaccines described above). This trial, known
as RV144 (150) was conducted in Thailand. This vaccine strategy is described as
using a canary pox viral vector carrying HIV-1-1 envelope gene gp120, Gag, and Pol
to prime the immune response, followed by the AIDSVAX gp120 subunit vaccine to
boost. The outcome of this trial is not promising: the vaccine efficacy is only 31.2%
in their modified intention-to-treat study involved 16,395 subjects. In addition, there
are no significant changes in the degree of viremia or the number of CD4+ T cells.
This limited protection although not promising, offers insight for further research.

What lessons shall we learn from these vaccine trial failures? First, we understand that
an effective vaccine should have the potential to stimulate both CD8+ T cell and B cell
response to multiple epitopes, especially to those highly conserved regions. In addition,
an effective vaccine that allows T cell response to the common epitopes of different
variants of the founder virus could inhibit viral immune evasion. Second, the fact that
bNAbs induced by these conventional vaccines are usually low in number, poor in
quality, and elicited slow in time reveals that a more reasonable strategy would be to
create a vaccine that exposes as many conserved epitopes as possible, and also stably
preserves the native form without denaturing in vivo. In addition, more advanced
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adjuvants and therapies that can protect bNAbs-producing B cells or rescue the
damaged or exhausted CD8+ T cells and bNAbs-producing B cells may be necessary
to work synergistically with vaccines. Third, it will be very wise to understand the HIV1-1 envelope structures both in a native form, and in a complex form with potent bNAbs
binding. Understanding the structures of the HIV-1-1 virion as well as the envelope
glycoproteins allows us to investigate the epitopes that are targeted by bNAbs, or to
find out how the conserved regions are shielded by the variable loops and glycans.

There is a remarkable endeavor in recent HIV-1-1 vaccine studies. In 2013, a study
carried in China designed a novel adjuvant for HIV-1 vaccine delivery (151). Fullerenol
is self-assembled into virus-sized nanoparticles, and they use this dual-functional nanoadjuvant to deliver a HIV-1-1 DNA vaccine. Surprisingly, this adjuvant not only shows
promising adjuvant activity, but also decreases the antigen dosage and immunization
frequency while maintaining decent immunity levels. What is more, the nano-adjuvant
promotes effector memory CD8+ T cells in immune response, which has great
significance in earlier immunity against HIV-1 infection. In November, 2015, a new
method investigating how HIV-1-1 vaccine induce humoral immunity, termed “systems
serology”, reported by Chung AW et al. (152), provides us more ideas to understand
the multi-dimensional relational comparisons in humoral immune response against
HIV-1-1 vaccine. Furthermore, researchers from Duke University designed a HIV-1
Env using the novel 3D-printing technique (153). A ligand-free HIV-1-1-Env trimer
was fixed in its native conformation, and epitopes were analyzed. These antigenicity-
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guided structural designs are promising for a new generation of vaccine antigens. In
February, 2016, one research team lead by Harvard Medical School and Beth Israel
Deaconess Medical Center, recombined an HIV-1-1 clade A Env gene into adenovirus
serotypes 26 and 35 (154). Assessment of the safety and immunogenicity of these two
adenovirus-vectored-HIV-1 vaccines showed that both vaccines elicited significant
immune responses without noticeable side effects in monkey model tests. This study
provides us ideas about designing a desirable HIV-1-1 vaccine delivery system, but
how long the protection lasts and how well the vaccine protects human after HIV-1
infection remains unknown. These recent HIV-1 vaccine studies, either focus on the
adjuvant development, on understanding the humoral response rationale beyond
vaccination, on choosing a safe and effective antigen delivery vector, or on a structural
basis to design immunogens with reasonable antigenicity, are very good examples
representing the promising directions of HIV-1 vaccine development.
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Chapter 2: Introduction and Objectives
The structure-based design of HIV-1 vaccine emphasizes the rationale on the structural
relationship between antigens and antibodies. This method is substantially rational and
sophisticated in designing immunogens to elicit potent neutralizing antibodies.
Traditional HIV-1-1 vaccine designs do not pay much attention to the structural
instability or the potential for antigen denaturing after in vivo antigen delivery, which
is likely one of the reasons why potent bNAbs cannot be elicited. It is in this context
that studies focused on structural-based design of HIV-1-1 vaccines have been started
recently (146, 155).

The envelope glycoprotein of HIV-1-1 is expressed as the gp160 precursor, which is
then proteolytically cleaved into gp120 and gp41 during maturation in the Golgi
apparatus (35, 155-158). The two glycoprotein subunits gp120 and gp41 are the sole
spikes on the surface of HIV-1 virion, so a large number of vaccine designs are based
on these glycoproteins. Naturally, these two glycoproteins are non-covalently linked
and are formed as heterodimers, and eventually function as trimers of gp120/gp41
dimers. Despite the fact that viral envelope protein complexes are well exposed on the
surface, generation of HIV-1-1-specific neutralizing antibodies are shown to be narrow
in breadth. As been discussed above, possible reasons may include viral mutation
resulting in immune evasion. However, recent studies focusing on the HIV-1-1
envelope trimer structures reveal that another HIV-1-1 immune evasion mechanism
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may be associated with the rearrangement of the envelope trimer structure during a prefusion to post-fusion transition (159-161). During recent years, the Cyro-EM technique
has brought the structure of a soluble HIV-1-1 envelope trimer to our horizons (159161). This trimer structure was represented in a cleaved state without gp41 MPER
region and cytoplasmic tail. Later, the crystal structure of this cleaved trimer captured
by antibodies PGT122 and 35O22 was also established. These findings make blueprints
for mapping the prevalence and location of effective HIV-1-1 immune recognition.

Over the past 20 years, substantial HIV-1-1 envelope subunits structures have been
obtained at atomic or near atomic levels. Some of these important findings include the
structure of the gp120 core and its interaction with CD4 molecule (162), and the
structure of post-fusion gp41 (163-165). In the context of the trimer, gp120 subunits
shield most of the gp41 subunit and becomes the most exposed subunit, so that gp120,
compared to gp41, has been more commonly studies (166)(167)(168)(169)(170). The
first generation of candidate immunogens was designed based on monomeric gp120
(146, 164, 165, 171-173). The peptide sequence of gp120 is made up of five conserved
regions and five variable regions (174-177), the five conserved regions together
represent the gp120 core. The gp120 core is shielded by highly glycosylated variable
regions, protecting the core from being neutralized.

Monoclonal antibodies (Mabs) against HIV-1-1 envelope proteins are primarily
generated from naturally infected human beings or other animals. Among these Mabs,
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a large number are antibodies that have no neutralizing ability. However, there are some
potent Mabs which are able to neutralize several primary HIV-1-1 isolates (165, 178,
179). These neutralizing Mabs include 2F5, 2G12 and lgG1b12. Other Mabs
particularly interact with the variable loops and are classified as V1/V2/V3 antibodies,
but they are however only able to neutralize certain epitopes, so their value in vaccine
development is less promising (178-188). The last group of antibodies directly targets
the CD4 binding site, called CD4-BS antibodies. These antibodies also provide limited
neutralizing effect, but they are able to neutralize laboratory-adapted isolates such as
MN27 and HXBc2 (189, 190) (191). X-ray studies looking at the crystal structures of
the HIV-1-1 gp120 (191)(192) core region demonstrated that the variable regions in
two isolates HXBc2 and YU2 share very little accordance in terms of neutralizing
antibody responses and coreceptor binding. However, the X-ray 3D crystal structures
of these two isolates are nearly identical (191, 193, 194).

Figure 3 represents the crystal structure of the gp120 core, which is composed of three
domains: the inner domain, outer domain and bridging sheet (198-201). Moreover, a
red circle at the junction of three domains indicates the location of the CD4 binding site.
Recent studies looking at the binding of the structure of gp120 to VRC01, suggests that
its binding site on gp120 seems to be, to some extent, identical to the CD4 binding site,
as shown in Figure 4. However, a closer look at their binding sites revealed that VRC01
majorly binds to the outer domain of gp120, whereas the CD4 binding site consists of
the junction of the three domains of gp120. These studies provide us with more details
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about the outer domain of gp120. Compared to the inner domain and bridging sheet,
the gp120 outer domain is relatively more stable, and is also highly conserved. One idea
is that by making the outer domain protein as an immunogen, VRC01-like antibodies
could possibly be induced. A recent study in our lab created two disulfide bonds to
stabilize the C-N terminal, as well as the 21/22 hairpin in the CD4-bound
conformation of the gp120 outer domain (195). Immunogenicity of that modified OD
has been evaluated and showed that OD2 (stabilized with additional two disulfide bonds
from OD1) compared to OD1, was able to induce and circulate a higher amount of
neutralizing antibodies in guinea pigs (196).

Based on that study, we have introduced

an additional S375W mutation to the CD4-bond conformation of outer domain, and
named it OD3, to further investigate its potential of inducing neutralizing antibodies
compared to OD1 and OD2. An X-ray crystal study of the gp120-CD4 binding complex
reveals how the structural conformation of gp120 differs from the unbound state, and a
thermodynamic study (195) of S375W gp120 binding to sCD4 reveals that there is less
of an enthalpic and entropic change exhibited upon CD4 binding, which confirms the
S375W-triggered CD4-bound conformation. The S375W-induced gp120 CD4-bound
conformation appears to be a valuable conformation for further studies in vaccine
design. We hope to make the gp120 outer domain a more stable immunogen and bring
insights for further HIV-1-1 vaccine development.
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Chapter 3: Materials and Methods
General Experimental Design
Figure 5 illustrates the general experimental design in this study. The objective of the
study is to evaluate the immunogenicity of our designed OD3 immunogen compared to
OD1 and OD2. Primers were designed to generate the S375W mutation by site-directed
mutagenesis, and the new gene segment was cloned into the expression vector pET28b.
Plasmids were transformed into E.coli BL21 (DE3) for protein expression and
purification. Purified samples were validated by SDS-PAGE, to evaluate immunogens’
purity, followed by Western-blot with antibodies targeting different epitopes of the
gp120 outer domain. Circular dichroism was conducted to confirm the secondary
structure of the immunogens and to ensure their folding status. Verified immunogens
were sterilized using the Minisart® 0.20 m non-pyrogenic single-use filter for guinea
pig immunization. A 63-day immunization protocol was followed. Guinea pig serum
was collected at different time points for immunogenicity studies. HIV-1-1
pseudotyped viruses were generated by transfection of viral envelope plasmid, a CMV
packaging plasmid and a luciferase plasmid into 293T cells. These pseudotyped viruses
were utilized in the viral neutralizing assay.

Virus Strains
Viruses used for the neutralization assay were pseudotyped HIV-1-1 viruses produced
by transfection of 293T cells with three plasmids: a plasmid carrying luciferase
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expressing gene (pHIV-1-luc), a plasmid packaging HIV-1 Gag and Pol gene (pCMV
Gag-Pol) and plasmids expressing the HIV-1-1 envelope proteins of isolate variants
(pSVIIIenv) (197, 198). Transfection of these three plasmid produces luciferaseexpressing HIV-1-1 isolates in 293T cells after three days of incubation.

Molecular Modeling and Designing of OD3
The glycoprotein-antibody complex, HIV-1-1 subtype B strain gp120 and the VRC01
monoclonal antibody complex were used as structural models to study and predict the
gp120 structure of the HIV-1-1 subtype C strain 1084i. Based on a paper published
from our lab (199), we designed the OD1 and OD2 immunogens using the software
Discovery Studio Client 3.5 (Accelrys, San Diego, CA). OD1 is the wildtype gp120
outer domain and OD2 refers to the disulfide bond induced gp120 outer domain. OD3,
used in this study, was modified from the OD2 protein with a serine to tryptophan
mutation at location 375. This S375W mutation was first assessed in a full length gp120
in 2002 (200). The S375W mutation resulted a tryptophan indole ring occupying the
Phe 43 cavity, which favors a gp120 conformation close to the CD4-bound state, which
was better recognized by either CD4 or CD4-induced antibodies, and less favorable to
CD4-binding-site antibodies. Considering the fact that S375 is located in the outer
domain of gp120, we introduced the S375W mutation and designed OD3 to test its
immunogenicity. All structural-based modification designs were performed on the
platform of Discovery Studio Client. We numbered the protein sequences of OD1, OD2,
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and OD3 based on the reference of the envelope sequence of the HIV-1-1 prototypic
HXBc2 strain (201).

Cloning and Expression of OD3
The gene design of OD3 was based on our previous work on OD1 and OD2, and all the
genes were designed using the HIV-1-1 subtype C strain 1084i (201). OD1 and OD2
were synthesized by GenScript®. Basically, the wildtype OD1 has 214 amino acids,
from 246 to 460 of gp120, and the design of OD2 was modified from OD1 to introduce
two disulfide bonds (4 cysteine substitutions were introduced at the amino acid
locations 257, 370, 425, and 472). In the design of OD3, a serine at the amino acid
location 375 was mutated to tryptophan (S375W) from OD2 by mutagenesis. To be
specific, the forward primer (5’-CGT TGC ATC ACC ATG CAC TGG TTC AAC TGC
CGT GGT-3’) and the reverse primer (5’-ACC ACG GCA GTT GAA CCA GTG CAT
GGT GAT GCA CAG-3’) were synthesized by GeneScript®. Primers were used in
site-directed mutagenesis and OD3 was cloned into the vector pET28b. All the genes
were designed with a 6xHis-tag at the N-terminus for the future purpose of protein
purification.

The designed OD3 gene was cloned along with OD1 and OD2 into the pET28b
expression vector (Novagen), and E.coli BL21 (DE3) was used as the protein
expression system. Sequence confirmation was conducted by Operon® to make sure
the open reading frame, the designed mutation as well as the N-terminal 6x histidine
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tag were correct and present. Three genes in pET28b were transformed into E.coli BL21
(DE3) competent cells. 60 L competent cells were mixed with 100ng plasmid of each
gene on ice for 10 minutes in a 1.5 mL Eppendorf tube. The tubes with plasmid and
cells mixture were then incubated in a 42°C water bath for 2 minutes. Tubes were then
placed on ice following heat shock for 5 minutes. 0.5 mL of LB Broth (Lennox) media
with no antibiotics was added into each tube containing the OD1, OD2, and OD3
plasmid transformed cells, and were then incubated in the 37 °C shaker at 200 rpm for
20 minutes. 50 L of cell culture suspension were then taken from each tube, and were
spread on LB agar plates supplemented with 50 mg/L kanamycin. After 14 hours of
incubation at 37°, single colonies from each of the 3 plates were picked up and grown
in 3 mL LB media with 50 mg/L kanamycin in the 37 °C shaker at 250 rpm until the
optical density reached between 0.4 and 0.6 at 600 nm. The cells were induced by
adding 1mM isopropyl-D-thiogalactopyranoside (IPTG) at a final concentration of 1
mM, and continuously grown for another 3.5 hours. All the bacterial culture was finally
harvested and collected by centrifugation at 6000 G for 15 minutes. The cell pellets
were washed once with STE buffer containing 100 mM NaCl, 10 mM pH 7.5 Tris, and
1 mM Ethylenedinitrilo tetraacetic acid disodium salt (EDTA). Cells were suspended
in STE+ buffer (100 mM NaCl, 10 mM pH 7.5 Tris, 1 mM EDTA, 0.5% NP40, 100
mg/L lysozyme, and protease inhibitors), and incubated on ice for 20 minutes. Cells
were then disrupted by sonication and were centrifuged at 14000 rpm at 4°C for 10
minutes. Both supernatant and cell debris were collected to determine whether the
protein of interest was in supernatant or insoluble fraction. An SDS-PAGE test followed
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by Coomassie blue staining and anti-6xHis western blot were conducted to determine
the existence of our protein of interest. We found that the majority of the recombinant
protein existed as inclusion bodies. The transformed strain E.coli BL21 (DE3)
containing each OD1, OD2, OD3 plasmid were made into glycerol stocks for further
experiments.

Immunogen Purification
OD1, OD2 and OD3 protein expression began by the inoculation from the glycerol
stock of E.coli BL21 (DE3) containing each OD1, OD2, OD3 plasmid into 3 mL LB
media with 50 mg/L kanamycin. 3 mL bacterial culture were then added into 300 mL
LB (1:100) with 50 mg/L kanamycin, then were incubated, induced with IPTG,
collected, washed, and lysed using the same method mentioned above. To purify the
recombinant protein as inclusion bodies, 4 subsequent washes were performed to
gradually increase the purity of our protein of interest. First, they were washed with 1x
PBS+0.1% SDS, then with 1x PBS+1% NP-40, then with 1x PBS+1% TritonX-100
and finally with 1x PBS+2 M urea. Short periods of sonication impulse were introduced
during the washes to better diffuse the inclusion bodies. The insoluble fraction after 4
washes was finally solubilized in 3 mL solubilization buffer (8 M urea, 50 mM NaCl,
20 mM Tris (pH=7.5), and 5 mM Dithiothreitol (DTT) at 4°C for 30 minutes. The
solubilized sample was then transferred into a dialysis cassette (Slide-A-LyzerTM G2,
Thermo Scientific). Our sample was then renatured by successive dialysis against the
refolding buffer at 4°C (pH=7.5 20 mM Tris, 400 mM L-Arginine, 1 mM EDTA, 5%
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glycerol, 0.4 mM Glutathione (GSH) and 1 mM Glutathione disulfide (GSSG)
containing 4 M, 2 M, 1M, 0M urea), for 2 hours, 8 hours, 8 hours, and 24 hours
respectively. The refolded protein samples then underwent an affinity purification
known as immobilized metal affinity chromatography. Ni-NTA resin beads (Thermo
Scientific) were used to further purify the protein. Protein purity was measured by
Coomassie blue staining and Western blot analysis. Concentration of the protein
samples was determined by a BCA protein kit (Pierce). Purified and renatured protein
samples were then used for further characterization.

Immunoblotting
Purified protein samples were loaded into a 10% SDS-denaturing gel along with
negative (bovine serum albumin (BSA)) or positive (recombinant gp120) controls. The
gels were run for 75 minutes at 60 volts. Nitrocellulose membrane transfer followed the
SDS-PAGE (204). After 30 minutes blocking with 5% non-fat dry milk in phosphatebuffered saline (PBS), nitrocellulose membranes were incubated for one hour at room
temperature with primary antibodies. Following six washing steps (five minutes each)
with PBS+0.1% Tween-20, horse radish peroxidase (HRP) conjugated secondary
antibodies were incubated with membranes for 30 minutes at room temperature. Six
washes were followed as explained previously. The outcome of antigen-antibody
binding was detected either using SuperSignal West Dura Extended Duration Substrate
kit (Pierce) or using a BioRad ChemiDoc (LiCor Inc., Lincoln, NE) (205).
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Secondary Structure Characterization
A desalting process was performed prior to the circular dichroism (CD) characterization.
A desalting column (zebaTM Spin Desalting Columns, 7K MWCO, 5 mL) was used to
remove L-arginine from the protein solution to avoid noisy signals. The instrument used
for CD is a Jasco J-815, which is equipped with a cell compartment with a Peltier-type
thermostat and a water circulator. The acquisition and data analysis are also from Jasco.
Data was recorded using either a 1 mm cell-path 300 L quartz cuvet or a 0.1 mm
15000 L circular quartz cuvet at 20°C. The data was exported in XY asci format and
analyzed with the program CD-Pro located at the DichroWeb site from the University
of London, for the purpose of estimation of the secondary structure of the protein. The
data was analyzed in the raw machine units (millidegrees) with the same resolution as
the acquired data (1 data point per nanometer). The cell path, average molecular weight
and protein concentration were provided prior to the fitting, which was carried out using
the various models available (CONTINLL and SELCON3 yielded the lowest RMSD
values) until a satisfactory fit was obtained. The results were imported into Sigmaplot
(SPSS) which was used to plot the data along with the simulated secondary structure
spectrum. Our three protein samples were measured at the same concentration of 0.35
g/ml, solubilized in buffer containing 20mmTris-HCl and 2mm EDTA at pH=8.0,and
the recording pathlength is 0.01 cm.
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Guinea Pig Immunization
The standard 63-day immunization protocol of Cocalico Biologicals, Inc. (CBI) for
guinea pigs was followed. 16 guinea pigs were assigned evenly into 4 groups:
inoculated with OD1, OD2, OD3 or adjuvant only (Complete Freund’s Adjuvant or
Incomplete Freund’s Adjuvant). Three booster injections were carried following the
first injection. Blood samples were collected from all guinea pigs on Day 0, prior to
immunization as prebleed samples; on day 35 as test bleed samples after 2 boosts on
day 14 and day 21; and on day 63 as exsanguination samples following the third boost
on day 49. Blood samples collected (pre-bleeds, test bleeds and final bleeds) were used
in antibody testing, ELISA and neutralization assays. All animal experiments were
performed according to the protocol approved by the IACUC of CBI (Reamstown, PA).

ELISA
Flat-bottom, with low evaporation lid 96-well plates (FalconTM) were coated with 200
ng per well of test protein (OD1, OD2 and OD3) diluted in coating buffer (15 mM
Na2CO3 and 35mM NaHCO3, pH 9.6). Prior to blocking, plates were washed with
phosphate buffered saline with 0.1% Tween-20 (PBS-T, Sigma-Aldrich) 3 times. Plates
were blocked with 200 μL/well blocking buffer (PBS-T with 5% milk) at room
temperature for 1 hour. After 3 washes with PBS-T, 100 μL/well of guinea pig sera
diluted in PBS-T at different ratios was added and incubated at room temperature for 2
hours. Plates were washed 5 times prior to the addition of 100 μL/well of HRPconjugated goat anti-guinea pig IgG secondary antibody (Jackson ImmunoResearch
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Laboratories Inc.), and incubated at room temperature for 2 hours. Plates were washed
5 times, and 100 μL/well SureBlue ReserveTM TMB substrate (KPL) was added and
incubated for 1 min in the dark. 100 μL/well of 1 M HCl was added to stop the reaction.
Absorbance data was collected at 450 nm using an ELX 800 UV universal microplate
reader (Bio-Tek Instruments).

Generation and Titration of Viral Stocks
HIV-1-1 isolates used for neutralization assay are pseudotyped HIV-1-1 viruses
produced by transfection of 293T cells with three plasmids: pHIV-1-luc, pCMV GagPol, and pSVIIIenv of different isolates, as mentioned above. Transfection of these
three plasmid produces luciferase-expressing HIV-1-1 isolates in 293T cells after a
three day incubation period. Transfected 293T cells were grown at 37°C with 5% CO2,
and maintained in DMEM medium with 584 mg/L L-Glutamine (Gibco), supplemented
with 10% FBS and 1X penicillin-streptomycin. Twenty-four hours prior to transfection,
1.5x106 cells were plated in 10 cm dishes. Cells were transfected by adding 6µg of
replication-deficient HIV-1 luciferase plasmid pHIV-1-luc, 2 g HIV-1-1 envelope
construct pSVIIIenv-Yu2/1084i/89.6/JRFL/HXBc2/ADA, and 2 µL CMV backbone
plasmid diluted in 1 mL unsupplemented DMEM. Polyethylenimine (PEI) was the
transfection reagent used in this experiment. Cell supernatants were collected at 72
hours post-transfection, and passed through a 0.45 µM syringe tip filter. The amount of
virus in the supernatants were measured by reverse transcriptase (RT) assay (202).
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Virus Neutralization Assay
The neutralization assay was based on methods previously described in our published
paper (199). TZM-bl cells were incubated at 37°C supplement with 5% CO2, and
maintained in DMEM medium containing 4.5 g/L D-glucose and 584 mg/L LGlutamine, supplemented with 10% FBS and 1X penicillin-streptomycin. One day prior
to the assay, cells for infections were seeded at 0.6x104 per well in 96-well plates, flatbottom, black-sided plates (Grenier Bio-One). In another separate 96-well plate, heatinactivated guinea pig serum was serially diluted to a final volume of 100 μL of cell
growth media, mixed with 2000 RT units of pseudotyped HIV-1-1 in 50 μL cell growth
media. The virus and cell mixtures were incubated for 1 hour at 37°C with 5% CO2,
and during this incubation, the TZM-bl growth media was replaced with 50 μL media
containing 160 μg/mL DEAE-Dextran (Sigma-Aldrich) (40 μg/mL final concentration).
The serum-virus mixture was added to cells and incubated at 37°C for 60 hrs. The
luciferase assay system (Promega) was used to detect Tat-inducible luciferase.
Luminescence was measured on a Veritas luminometer (Turner Biosystems). Percent
neutralization was determined using the following equation: (1 – ((test well – cell
control well) / (virus control well – cell control well))) x 100 (203).
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Chapter 4: Results and Discussions
Structural Based Immunogen Design
The outer domain (OD) of HIV-1-1 gp120 envelope glycoprotein contains epitopes for
CD4-BS antibodies due to the biological nature of its interactions with CD4 molecule.
Some CD4-BS bNAbs neutralize 90% of HIV-1-1 isolates, such as VRC01.
Considering the fact that the outer domain is relatively more stable than other domains
of gp120, the outer domain has been considered to be a potential HIV-1-1 vaccine
immunogen candidate. However, efforts to elicit bNAbs with the outer domain have
not been successful. Studies of the outer domain crystal structures revealed that the
when the outer domain only was represented in a truncated form, the protein structure
does not remain consistent with the native form when the outer domain was presented
within gp120 (204)(195) (205). To be more specific, the C and N terminal of OD1
(refers to the truncated outer domain without any structural modifications) are more
widely open, and the 20-21 hairpin is less closed to the outer domain core and the
structure around the Phe 43 cavity does not exactly resemble the native form. Here, we
based our design the OD2 structure and introduced a S375W mutation to further stable
the outer domain. In summary, an OD3 immunogen design involves the following
strategies: 1) keeping the outer domain core structure by removing all the variable loops;
2) introducing two disulfide bonds to stabilize the C-N termini and the β20-21 hairpin;
3) introducing an S375W mutation to have the indole ring from tryptophan filled into
the Phe 43 cavity.
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Figure 6 represents details of superimposed structures of the OD3 compared to OD1,
and Figure 7 shows the designed structures of three proteins, and the amino acid
locations of the mutations for the disulfide bonds and S375W. The outer domain
designed in this way is predicted to be more favorable to CD4-BS bNAbs binding and
thus is more promising to recruit potent bNAbs such as VRC01-like antibodies. The
highly conserved outer domain, as mentioned previously, has more antigenic
importance in eliciting effective antibodies than the variable loops. In our design, the
variable loops have been completely removed so that the outer domain core is free from
variable loop masking and glycan shielding. Furthermore, the S375W mutation is
predicted to further stabilize the outer domain into a CD4-bound state, which is more
vulnerable to CD4-BS antibody neutralizing. This taken together may explain why our
OD3 design is able to induce higher level of potent neutralizing antibodies compared
to OD1 and OD2, which will be further discussed.

Generation and Validation of Immunogens
The designed OD3 gene was cloned into a bacterial vector pET28b and expressed in
the E. coli strain BL21 (DE3). The strain BL21 is an E. coli K12 derivative which
contains mutations in both the thioredoxin reductase and glutathione reductase genes
that allows an intracellular environment for proper disulfide bond formation. OD3 was
expressed along with OD1 and OD2 in this strain and was induced by IPTG for optimal
recombinant protein expression. Purification of these three immunogens was achieved
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by washing inclusion bodies followed by protein refolding dialysis and 6x His-tag metal
affinity chromatography purification. A SDS-PAGE gel, shown in Figure 8, reflects
the size and purity of three proteins. The clear bands around the molecular weight of 25
kDa marker suggested the recombinant proteins (weight 22.2 kDa) were detected at
correct size. Proteins were concentrated by Pierce™ Protein Concentrators PES, 10K
MWCO to a range from 0.2-2 g/l for experiments.

Purified proteins were further validated by immunoblotting, as shown in Figure 9. To
be more specific, the CD4-BS monoclonal antibodies F105, VRC01 and b12
demonstrated binding affinity to all three proteins. In addition, polyclonal antibodies
including patient sera and a commercially available anti-gp120 (abcam Inc. ab53840)
all showed distinct bands responding to the immunogens. Last, a CD4 induced
monoclonal antibody 17b, also showed binding activity to all three immunogens but
was relatively weaker than other antibodies.

Secondary Structure Verification
Circular dichroism (CD) is an excellent method of rapid protein secondary structure
determination. Typically, protein samples with α-helixes will show negative ellipticity
bands at 222 nm and 208 nm and a positive band at 193 nm (206), whereas protein
samples containing β-sheets have negative bands at 218 nm and positive bands at 195
nm (207). Proteins with disordered turns have very low ellipticity above 210 nm and
negative bands near 195 nm (208). Figure 10 shows the secondary structure analytical
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results of our three outer domain immunogens (OD1, OD2 and OD3) obtained through
circular dichroism. The data was analyzed by software CDSSTR and is summarized in
Table 1. The analytical results showed that: 1) OD2 is different from OD1 with two
disulfide bonds, and this difference is reflected by the increase in the OD2 positive
ellipticity absorbance at 193nm and same absorbance at 195nm. This result suggested
that the two disulfide bonds help the protein organize some unordered turns into wellordered α-helix-like structures, without disrupting β-sheets. 2) OD3 is different from
OD2 with a S375W mutation, which stabilizes the outer domain to a CD4-bound state.
In the Figure 10, an OD3 curve not only showed positive ellipticity absorbance at both
193nm and 195nm, but also showed an increase in the negative band at 208nm, 218 nm
and 222 nm, suggesting more unordered peptide structures transferred to α-helixes,
helixβ-sheets structures and ordered turns. These data provided us an idea that our
S375W mutation in outer domain is very likely to stabilize the immunogen by making
the outer domain secondary structure more organized.

In the total amino acid sequence, there are 26 amino acids organized in alpha helices
and 70 in beta sheets, out of a total of 195. Thus the composition as far as secondary
structure is predicted to be 13 % alpha helical and 36% beta sheet. This is in good
agreement with the observed results for the beta sheets. Note that type 1 helix which is
the most common, is usually more accurate, yielding 13-14%, in agreement with the
predicted secondary structure.

47

Immunogenicity of Designed Immunogens in Guinea Pigs
The purified, validated protein immunogen samples were then utilized in immunization
studies. We ordered 16 guinea pigs and evenly divided them into 4 groups, each of
those was inoculated with our three immunogens respectively, and one group was
inoculated with adjuvant only as negative control. The Freund’s adjuvant system
(CFA/IFA) was used for this immunization test. Figure 11 shows the basic protocol
and timeline of the immunization carried out in this study. Blood samples were
collected at three time points: at day 0, which is referred to as the pre-bleed serum
samples used as a negative control; at day 35, which is referred to as the test bleed
serum samples, and at day 63, the last day, which is referred to as the final bleed serum
samples. All inoculations, boosts, and blood sample collection was conducted by
Cocalico Biologicals, Inc. in Reamstown, PA. Serum samples of all guinea pigs were
shipped overnight in dry ice to us and were properly stored at -80°C. These serum
samples were used in immunogenicity studies including Western-blotting, ELISA and
virus-serum neutralization assay.

Antibody Specificity Validation
Immunogenicity of our designed immunogens was first evaluated by Western-blotting
assay to see whether there were antigen specific antibodies elicited in the immunized
guinea pigs. The data from these experiments is shown in the Figure 12. We blotted
each antigen with the final bleed serum collected from all groups. All sample groups
inoculated with their assigned antigens (OD1, OD2 and OD3) showed related binding
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activity. And the clear bands indicated our purified antigens remained stable in the
storage condition of -80°C. In addition, all groups inoculated with any antigens (except
for the group immunized with adjuvant only) showed that their serum not only contains
antibodies against gp120 outer domain. Instead, as we predicted, no guinea pigs elicited
outer domain specific antibodies when were just inoculated with adjuvant (only some
results are shown here). These results proved the inoculation of our designed
immunogens successfully induced outer domain specific antibodies.

Antibody Titer Determination
In order to further evaluate the immunogenicity of our designed antigens, typically, to
compare the immunogenicity differences between the three antigens, an ELISA assay
was conducted and the results compared the total outer domain-specific antibodies
induced by three antigens in guinea pigs. As previously mentioned, “pre-bleed”, “test
bleed” and “final bleed” refers to serum samples collected from day 0, day 35 and day
63 respectively. Figure 13, shows the data combining ELISA panels from the pre-bleed,
test bleed, and final bleed of four groups. The three panels on the Y-axis represent the
pre-bleed, test bleed and final bleed antibody titers compared in four groups, whereas
the four panels on the X-axis represent the antibody titers in four groups immunized
with OD1, OD2, OD3, ADJ (adjuvant only). In general, before inoculation, of all
groups, no guinea pig individuals contain outer domain specific antibodies, reflected
by the antibody titers of pre-bleed panels, which were all negative background.
However, after antigen inoculation and two boosts followed at day 14 and day 21, test
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bleed serum from day 35 showed evidence of outer domain specific antibody generation.
There were no significant individual difference among all 12 guinea pigs in group one,
two and three, except for one case in the OD3-immunized group, in which one guinea
pig seemed to generate lower titers of outer domain specific antibodies. The difference
is significant at the serum dilution ratio of 1:100 to 1:2500. However, when we looked
at the final bleed panels, we found that although the individual differences are still not
significant in all groups, the guinea pig in OD3-immunized group who showed a lower
antibody titer at day 35 recovered with higher amounts of antibody, making the
individual difference less significant at day 63 than day 35. This increase in antibody
titer is supported from the third boost in day 49, reflected in the OD3 immunized test
bleed and final bleed panels, in which the antibody titers (absorbance at 450nm)
increased from 1.5 to 2.2. Moreover, antibody titers are slightly increased in guinea
pigs at day 63 than that at day 35, although the difference in OD3 immunized group is
less significant. This result suggests that the third antigen boost provided some limited
help in recruiting antigen-specific antibodies. Lastly, no HIV-1-1 outer domain specific
antibodies were found in all adjuvant immunized guinea pigs. It is therefore confirmed
again that antibodies found in the immunized guinea pigs were specifically induced by
the immunogens of the outer domains (OD1, OD2 and OD3).

Another important analysis is to evaluate the antigenic differences among these three
immunogens, and the differences can be more easily assessed in Figure 14, which
reorganizes the ELISA data in another way, represented as bar charts. From this figure
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we can tell that all three antigens induced a significant amount of antibodies compared
to adjuvant immunized groups. This figure however cannot detect any significant
differences between the OD1 and OD2 groups, but there is a significant difference when
comparing the antibody titers between OD3 and the other two groups, from which we
found that at 1:100 serum dilution ratio, the antibody titers of OD3-immunized groups,
reflected by absorbance at 450 nm, showed an average value of 2.87 in the test bleed
panel and 3.06 in the final bleed panel. Similar results were obtained at a lower serum
dilution ratio of 1:500 and 1:2500, suggesting that this assay has some value to
distinguish the antigenic differences between the three antigens, reflecting a higher
amount of the total antigen specific antibody titers in the OD3 immunized group.

Taken together, these results reveal that: 1) there are very small individual differences
in the antibodies elicited between the four guinea pigs in the same groups; 2) there is
some effect of inducing a higher amount of antigen-specific antibodies from the third
boost in OD1 and OD2 group, but no significant increase in OD3 group; 3) there is no
significant difference in the total antigen-specific antibodies between the OD1 and OD2
groups, but antigen specific antibody titers are significantly higher in OD3 groups.
However, there is a need to further investigate the antigenicity difference of the three
antigens and thus the virus-serum neutralization assay is needed to compare the
differences of their antigen-specific broad neutralizing antibody titers.
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Serum Neutralization against Diverse Viral Strains
In order to evaluate the immune response to the antigens resulting in antigen-specific
HIV-1-1 neutralizing antibodies, we investigated the neutralizing abilities of serum
from guinea pigs in all groups. Six HIV-1-1 isolates from subtype B and C including
five primary isolates YU2, ADA, 89.6, 1084i, JRFL and one lab-adapted strain HXBc2 were evaluated in this assay. Figure 15 compares the neutralizing activity of the
pre-bleed serum, test bleed serum and final bleed serum among the three antigens. Each
panel line on the X-axis represents one HIV-1-1 isolate involved in the neutralizing
experiment. Clearly, the figure points to a conclusion that, compared to the serum
collected in day 0, all antigen-immunized guinea pigs at day 35 and day 63 generated
neutralizing antibodies against all six HIV-1-1 isolates. However, the neutralizing
activities differ among the three antigen-immunized groups. To be specific, for all
panels, OD2 and OD3 are more capable of inducing neutralizing antibodies against all
six HIV-1-1 isolates than OD1. Overall, there is no significant percentage of
neutralization difference between the test bleed and final bleed serum in all antigenimmunized groups, for any virus isolates. The only exception was the isolate 89.6
neutralized by OD3 serum, in which the final bleed serum remains stronger protection
at all four serum dilution ratio. Previous ELISA data showing no significant difference
in the total antibody titer in all groups may explain the insignificance of neutralizing
antibody titers between the test and final bleed sera in these groups. The exception of
89.6 being neutralized at a higher percentage by OD3 final bleed serum than test bleed
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serum may be explained by the fact that 89.6 isolate is somehow more sensitive for
serum neutralizing when the total antigen specific antibody titers are at a higher amount.
The fact that overall there is no significant difference between test bleed and final bleed
serum neutralizing activities suggests that during the guinea pig immune response,
though the total antigen-specific antibodies were continuously recruited after the third
boost, the level of broad neutralizing antigen-specific antibodies remained the same,
indicating either there is an antigenic limit for these antigens to induce neutralizing
antibodies, or the total neutralizing antibodies are all induced at day 35 so that there are
few remaining neutralizing antibodies induced by the third boost.

To compare the biological activity of the neutralizing antibodies in guinea pig serum
induced by our designed antigen OD3, to the wild type OD1 and two-disulfide-bond
OD2, the original data is reorganized into Figure 16. Each panel on the X-axis again
represents one HIV-1-1 isolate neutralization, but each of the 6 panels on the Y-axis
are serum from day 0, day 35 or day 63. As negative controls, pre-bleed sera is not
supposed to have neutralizing antibodies, which is clearly represented by the day 0
panels, showing that there are no HIV-1-1 neutralizing antibodies that exist before
antigen inoculation. Furthermore, serum from day 35 and day 63 show all three antigens
elicited neutralizing antibodies, but the neutralizing activities are different. Generally,
OD1 induced less neutralizing antibodies, and the percentage of viruses neutralized by
OD1-immunized serum is only slightly larger than that of adjuvant alone. Although this
is not necessarily true in the cases of YU2 and JRFL, the overall performance of OD1
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was not satisfactory. Serum from OD2-immunized guinea pigs showed significantly
stronger protection than the OD1 group. In Figure 16 we show that OD2-immunized
sera from both day 35 and day 63 neutralized a higher percentage of viruses in all HIV1-1 isolates than OD1. Furthermore, OD2-immunized sera from day 63 reduced 1084i
and JRFL viral infection by 81% and 79% respectively, compared to the OD1 group,
which reduced infection by 62% and 43% respectively. These results suggest that the
disulfide bonds formation, to some extent stabilized the immunogen to become more
immunogenic in terms of inducing neutralizing antibodies. Moreover, serum from the
OD3-immunized group contains more neutralizing antibodies than the OD2 group. The
data in Figure 16 shows that OD3-induced neutralizing antibodies were more potent
than OD2 in neutralizing five of the six HIV-1-1 isolates: 89.6, ADA, HXBc2, YU2
and 1084i. In the case of the HIV-1-1 isolate JRFL although there is no significant
difference between OD2 and OD3 in antibody titers, the percentages of viral reduction
were quite comparable.

Finally, data in Figure 17 compares the neutralizing activity of OD3-immunized serum
in six HIV-1-1 isolates and one non-HIV-1-1 virus strain AMLV (Amphotropic Murine
Leukemia Virus). The non-HIV-1-1 AMLV served as a good negative control,
reflecting that the neutralizing antibodies are HIV-1-1 specific since they did not
neutralize AMLV. Among these HIV-1-1 isolates, the dual-tropic 89.6 is the most
vulnerable strain to OD3-induced antibody neutralization, followed by the lab-adapted
strain HXBc2. On the other hand, YU2, and ADA are relatively more challenging for
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neutralization. However, all of these isolates are neutralized by OD3-immunized serum
at 70% or higher at the 1:20 serum dilution ratio, suggesting OD3 to be a valuable
immunogen for further characterization.

Taken together, the virus neutralization results showed that the disulfide-stabilized
OD2 immunogen had better neutralization activities than the wild-type outer domain
(OD1), and the S375W-stablized OD3 had the best neutralizing activity against various
HIV-1-1 isolates. The S375W mutation serves a role in better stabilizing the
immunogen in a way that is favorable to elicit potent neutralizing antibodies against
heterologous HIV-1-1 isolates. This example of design using structural information
demonstrated that structural-based modification for immunogen stabilization is a better
strategy for improving vaccine immunogen design.

55

Chapter 5: Summary
Our designed OD3 was purified at an optimal purity, and validated by Western blots.
The secondary structures of all three immunogens were evaluated and the designed
OD3 was found to be more organized in the secondary structure. The immunogenicity
of the OD3 immunogen designed with the S375W mutation and two disulfide bonds
has been evaluated clearly in guinea pigs. Compared to OD1 and OD2, OD3 induces a
higher level of both total antigen-specific antibodies and neutralizing antigen-specific
antibodies. Our experimental results suggest that a structural-based vaccine design is a
better strategy compared to conventional vaccine designs using killed or subunit
particles without any structural modifications. Due to the breadth limitedness of this
project, there are some imperfections in applying our designed OD3 vaccine. First,
although OD3 induces both total and neutralizing antigen-specific antibodies higher
than OD1 and OD2, and even though these antibodies are capable of neutralizing
diverse HIV-1-1 isolates, these antibodies did not reach 100% neutralization against
any HIV-1-1 isolate at the lowest serum dilution ratio. Second, although the ELISA
assay showed that there is a significant amount of antigen-specific antibodies even
when the serum was diluted to 1:2500, our serum lost its neutralizing activity at a serum
dilution lower than 1:180. Taken together, this outer domain stabilization largely
improved the outer domain’s immunogenicity compared to the native wild type,
however more efforts are needed to make this immunogen to become applicable. Other
structural-based immunogen designs may work synergistically with our strategy. For

56

example, structural-based designs targeting the MPER domain of gp41 may work
together with the outer domain in inducing potent broad neutralizing antibodies. Also,
novel adjuvants and vaccine delivery methods may help to improve the
immunogenicity of the structural-based designed vaccines and finally provide us a
potent vaccine that is capable of inducing both T cell and humoral immunity to
eliminate HIV-1-1.

Tables and Figures
Table 1: Compositions of the secondary structures in OD1, OD2 and OD3. [Back to
text]

Secondary
Structures
Helix1
Helix2
Strand1
Strand2
Turns
Unordered

Immunogens
OD1 (%) OD2 (%) OD3 (%)
14
16
17
8
9
8
21
21
21
14
15
17
22
23
25
21
16
12
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Figure 1: Diagram of an HIV-1 virion structure. (Adapted from the website of
Wikipedia, the free encyclopedia) [Back to text]

Figure 2: Schematic presentation of HIV-1-1 genomic organization. (Adapted from
HIV-1 Sequence Compendium 2015). [Back to text]
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Figure 3: The gp120 core structure: Inner Domain (ID), Outer Domain (OD) and
Bridging Sheet (BS). [Back to text]

Notes: The CD4-binding site (CD4-BS) is located at the junction of three domains
indicated by the red circle. The picture was adapted from Kwong et al. (Nature. 1998
Jun 18; 393(6686):648-59).
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Figure 4: Superimposed CD4 receptor and VRC01 antibody bindings to the gp120 of
HIV-1-1. [Back to text]

Notes: The gp120 is depicted in a surface model. The gp120 inner domain (ID) is in
gray, and outer domain (OD) in cyan. The HIV-1 receptor CD4 (color yellow) and
neutralizing antibody VRC01 are depicted in ribbon strips (colored red for the heavychain (HC), magenta for the Light-chain (LC)).
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Figure 5: Schematic presentation of the general experimental design. P-OD2, plasmid
OD2; P-OD3, plasmid_OD3. [Back to text]
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Figure 6: Superimposed OD3 (color cyan) and the wild-type outer domain OD1 from
HIV-1-1 strain HXBc2, PDB # 4I3S, color purple) structure. [Back to text]

Notes: 4I3S refers to the sequence of HXBc2 outer domain. Od3_1084i refers to the
OD3 gene mutated from 1084i outer domain. Dis-1: disulfide bond-1, was created to
stabilize the C-N termini, and Dis-2: disulfide bond-2, was created to stabilize the
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beta 20-21 hairpin. The OD1 structure is from published data on the HXBc2 outer
domain, and OD3 structure was modeled in Discovery Studio Client 3.5 based on the
outer domain sequence of 1084i isolate. [Back to text]

Figure 7: 3D modelling of the three designed immunogens and their amino acid
changes. [Back to text]

Notes: The outer domain was cut-off from the position 254 of full length gp120
molecule, which corresponds to the position 1 of the outer-domain numbering in this
diagram. Based on the full length sequence of gp120 standard numbering system
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(209), these mutations in this diagram are also indicated as follows: Dis 1: Dis 1:
disulfide bond-1, T/C257-G/C472 (T/C4-GC185 in this table); Dis 2: disulfide bond2, E/C370-N/C425 (E/C97-N/C139); S375W (S/W102).
Figure 8: Antigen purification represented by SDS-PAGE. [Back to text]

Figure 9: Characterization of the three immunogens by Western blot. [Back to text]

Notes: After SDS-PAGE and membrane transfer, protein samples of OD1, OD2, OD3
and BSA were probed with pooled serum from HIV-1-1 positive patients, anti-gp120
polyclonal antibody, CD4-BS monoclonal antibodies VRC01, F105, b12 or b12, and
CD4-induced monoclonal antibody 17b.
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Figure 10: Circular dichroism spectra of three immunogens with representative
secondary structures. [Back to text]

Notes: CD spectra of OD1 (black), OD2 (orange), and OD3 (green) at pH 8.0, room
temperature. Spectral data analysis was performed by Dr. Javier Seravalli in the UNL
protein core facility.

Figure 11: Guinea pigs immunization protocol. [Back to text]
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Figure 12: Western blot analysis of antisera from immunized guinea pigs. [Back to text]

Notes: Each band represents one independent Western blotting experiment. 4 serum
samples from each group were used as the primary antibody against the assigned
immunogens. All antigen-immunized groups showed antibody-binding activity to
gp120, and here only one is shown as a positive control. All adjuvant-immunized
group showed no antibody binding activity to OD1, OD2, OD3 and BSA (shows in
Adjuvant 1, 2, 3, and 4 respectively).
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Figure 13: ELISA analysis of antisera from immunized guinea pigs and their
individual antigenic differences. [Back to text]

Notes: 96-well plates were coated with three antigens, then were probed with
dilutions of pre-bleed serum (day 0), test bleed serum (day 35, or final bleed serum
(day 63). Experiments were performed in triplicate and figures represent an average
data of multiple experiments.
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Figure 14: ELISA analysis of antisera from immunized guinea pigs comparing
antigenic differences among three immunogens. [Back to text]
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Figure 15: Virus neutralization assay of antisera from immunized guinea pigs
comparing serum neutralizing activities at different time points. [Back to text]
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Notes: Neutralization assays of antisera from four groups of antigen-immunized or
adjuvant-immunized groups. Neutralization activities were represented as the
percentage (%) of reduction in relative luciferase units compared to wells with virus
and cells only. Experiments were performed in triplicate and figures represent an
average data of multiple experiments.
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Figure 16: Virus neutralization assay of antisera from immunized guinea pigs
comparing serum neutralizing activities of three immunogens. [Back to text]
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Notes: Neutralization assays of antisera from four groups of antigen-immunized or
adjuvant-immunized groups. Neutralization activities were represented as percentage
(%) of reduction in relative luciferase units compared to wells with virus and cells
only. Experiments were performed in triplicates and figures represent an average data
of multiple experiments.

Figure 17: Virus neutralization assay of antisera from OD3-immunized guinea pigs
comparing serum neutralizing activities against diverse HIV-1-1 isolates and nonHIV-1-1 isolate. [Back to text]

Notes: Neutralization assays of antisera from four groups of antigen-immunized or
adjuvant-immunized groups. Neutralization activities were represented as percentage
(%) of reduction in relative luciferase units compared to wells with virus and cells
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only. Experiments were performed in triplicates and figures represent an average data
of multiple experiments.
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